<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E8EE1BC9-799D-4921-8C12-8689B9552A74"><gtr:id>E8EE1BC9-799D-4921-8C12-8689B9552A74</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Frampton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14107"><gtr:id>978FF501-0A9E-44B5-BD9B-853F8F1BF0B4</gtr:id><gtr:title>University of Birmingham MRC Confidence in Concept 2014: Open Innovation Through Local Integration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14107</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>600000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Provided is a method of facilitating the determination of treatment of a subject displaying atrial fibrillation, the method comprising determining a level of pitx2c expression in a sample from the subject and selecting a treatment based upon the level of pitx2c expression. Treatment with a sodium channel blocker may be selected if the level of pitx2c expression is determined to be reduced or below a predetermined threshold. Also provided are an assay system and a kit for use in the methods of the invention.</gtr:description><gtr:grantRef>MC_PC_14107</gtr:grantRef><gtr:id>E3EA4123-8455-485C-8019-CEA0BCAAE6DB</gtr:id><gtr:impact>Dicsussions and collaborations.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58ca78059de593.58560801</gtr:outcomeId><gtr:patentId>WO2015140571 (Prof. Paulus Kirchhof)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Atrial Fibrillation Therapy</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method for identifying whether or not it may be appropriate to administer to a subject a therapy for alleviating any potential consequences which may arise due to the subject having an atrial fibrillation (AF), the method comprising detecting, in a sample of fluid from the subject, a level of ccl21 and/or ddit4 expression and determining whether or not it may be appropriate to administer to the subject a therapy for alleviating any consequences which may arise due to the subject having AF, based upon the ccl21 and/or ddit4 expression level detected. Also provided are an anticoagulant or other AF therapy and a method of administering an anticoagulant drug or another AF therapy.</gtr:description><gtr:grantRef>MC_PC_14107</gtr:grantRef><gtr:id>8FA3EA9F-2CC6-46E5-89BD-B40E16541643</gtr:id><gtr:impact>Collaborations and discussions.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56df03694d0820.09617576</gtr:outcomeId><gtr:patentId>GB 201413081 (Prof Paulus Kirchhof)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>MARKERS FOR ATRIAL FIBRILLATION (AF)</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin,or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.</gtr:description><gtr:grantRef>MC_PC_14107</gtr:grantRef><gtr:id>DC76244B-A57B-4377-B114-0488057A62D0</gtr:id><gtr:impact>Discussions &amp;amp; collaborations.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58ca7c240e8297.79081707</gtr:outcomeId><gtr:patentId>WO2016034851 (Dr Alexandra Sinclair)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Elevated Intracranial Pressure Treatment</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>48F8FF65-8ED9-4AA7-BBDC-B022CB3A190B</gtr:id><gtr:title>Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfca19140fc82c71b5f5ce6f7e3f2d93"><gtr:id>cfca19140fc82c71b5f5ce6f7e3f2d93</gtr:id><gtr:otherNames>AlAmri MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>5a2fd6b511ea90.01910425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>167CA8C8-DB67-484E-86E7-362CEB5DED40</gtr:id><gtr:title>Towards the Development of Small-Molecule MO25 Binders as Potential Indirect SPAK/OSR1 Kinase Inhibitors.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20fde76ba9c738639cdb0adb3a6c46cb"><gtr:id>20fde76ba9c738639cdb0adb3a6c46cb</gtr:id><gtr:otherNames>Kadri H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>5a2fd582610506.61080531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E43AF01-C58A-4128-B40E-D97E3BCA2AA6</gtr:id><gtr:title>PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects&amp;nbsp;of&amp;nbsp;Sodium-Channel Blockers.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad3c819b2eb3891683c5f2ab8ac3ab98"><gtr:id>ad3c819b2eb3891683c5f2ab8ac3ab98</gtr:id><gtr:otherNames>Syeda F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>58c822f1db6497.77908660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE666FDE-706E-4AA0-8A8B-9D79C7472D5D</gtr:id><gtr:title>A Regional Reduction in Ito and IKACh in the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential Prolongation and Increased Ectopic Activity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7337f21508b86034e3565ff97f5cea4"><gtr:id>a7337f21508b86034e3565ff97f5cea4</gtr:id><gtr:otherNames>Holmes AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c822f22dd285.04863116</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14107</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>